{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:05:34Z","timestamp":1781755534976,"version":"3.54.5"},"reference-count":79,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Major progress has been made in the upfront treatment of multiple myeloma, but the disease ultimately relapses and leads to death in the vast majority of those afflicted. New treatment strategies and modalities are necessary to treat myeloma in relapse, particularly in cases of triple-refractory status defined by disease progression during or shortly after treatment with immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibody therapy. In this manuscript, we review recent promising developments in the treatment of triple-class refractory myeloma including bispecific antibodies and T cell engagers, chimeric antigen receptor cellular therapies, as well as chemotherapeutics with novel mechanisms of action.<\/jats:p>","DOI":"10.3390\/curroncol29070355","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T21:25:00Z","timestamp":1656019500000},"page":"4464-4477","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9493-7221","authenticated-orcid":false,"given":"Margaret E.","family":"Stalker","sequence":"first","affiliation":[{"name":"School of Medicine, University of Colorado, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer M.","family":"Mark","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, University of Colorado, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"ref_1","unstructured":"(2021, September 06). Key Statistics About Multiple Myeloma. Available online: https:\/\/www.cancer.org\/cancer\/multiple-myeloma\/about\/key-statistics.html."},{"key":"ref_2","unstructured":"(2021, March 11). Relative Survival for Multiple Myeloma. Available online: https:\/\/themmrf.org\/multiple-myeloma\/prognosis\/understanding-survival-statistics\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000\u20132014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2013","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Myeloma, Clinically relevant end points and new drug approvals for myeloma","volume":"22","author":"Anderson","year":"2007","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","article-title":"Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With \u22653 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD","volume":"21","author":"Usmani","year":"2016","journal-title":"Oncologist"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bjh.12198","article-title":"A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma","volume":"160","author":"Petrucci","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1182\/asheducation-2014.1.262","article-title":"A practical approach to relapsed multiple myeloma","volume":"2014","author":"Mikhael","year":"2014","journal-title":"Hematology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): A randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1445-5994.2012.02867.x","article-title":"Relapsed multiple myeloma: Who benefits from salvage autografts?","volume":"43","author":"Chow","year":"2012","journal-title":"Intern. Med. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41375-020-0948-0","article-title":"Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: The randomized GMMG phase III trial ReLApsE","volume":"35","author":"Goldschmidt","year":"2021","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjh.12325","article-title":"D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma","volume":"161","author":"Gerrie","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3109\/10428194.2012.733879","article-title":"Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents","volume":"54","author":"Ronchetti","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_17","first-page":"bcr-2017","article-title":"Treatment of relapsed multiple myeloma complicated by cardiac extramedullary plasmacytoma with D-PACE chemotherapy","volume":"2018","author":"Toocheck","year":"2018","journal-title":"BMJ Case Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1182\/blood.V128.22.5676.5676","article-title":"High-Dose Cyclophosphamide in Highly Refractory Multiple Myeloma Patients as a Bridge to Further Novel Therapies","volume":"128","author":"Nikonova","year":"2016","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.clml.2019.05.001","article-title":"Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia","volume":"19","author":"Tabchi","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: Rebirth of an Old Drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2047-783X-15-1-13","article-title":"Bendamustine in patients with relapsed or refractory multiple myeloma","volume":"15","author":"Michael","year":"2010","journal-title":"Eur. J. Med Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood.V128.22.488.488","article-title":"Venetoclax Monotherapy for Relapsed\/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_26","unstructured":"(2022, March 11). FDA Warns about the Risks Associated with the Investigational Use of Venclexta in Multiple Myeloma, Available online: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm634120.htm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL -2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma","volume":"96","author":"Kaufman","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2040620720930629","DOI":"10.1177\/2040620720930629","article-title":"Selinexor in relapsed\/refractory multiple myeloma","volume":"11","author":"Richter","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective Inhibition of Nuclear Export with Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/blood-2018-99-116663","article-title":"Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM","volume":"132","author":"Chari","year":"2018","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Miettinen, J., Kumari, R., Traustadottir, G., Huppunen, M.-E., Sergeev, P., Majumder, M., Schepsky, A., Gudjonsson, T., Lievonen, J., and Bazou, D. (2021). Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. Cancers, 13.","DOI":"10.3390\/cancers13071527"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Mateos, M.-V., Blad\u00e9, J., Bringhen, S., Ocio, E.M., Efebera, Y., Pour, L., Gay, F., Sonneveld, P., Gullbo, J., and Richardson, P.G. (2020). Melflufen: A Peptide\u2013Drug Conjugate for the Treatment of Multiple Myeloma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103120"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S2352-3026(20)30044-2","article-title":"Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): A multicentre, international, open-label, phase 1\u20132 study","volume":"7","author":"Richardson","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S2152-2650(21)02124-8","article-title":"OAB-050: OCEAN (OP-103): A Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)","volume":"21","author":"Schjesvold","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2020.38.15_suppl.8500","article-title":"First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Richardson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2019.37.15_suppl.8006","article-title":"First clinical (phase 1b\/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"37","author":"Lonial","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: More room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"611366","DOI":"10.3389\/fimmu.2021.611366","article-title":"Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment","volume":"12","author":"Yan","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood\u2013Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-134383","article-title":"Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma","volume":"136","author":"Kansagra","year":"2020","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-136360","article-title":"Cytokine Release Syndrome in Patients with Relapsed\/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b\/2 CARTITUDE-1 Study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2018-99-116953","article-title":"Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2018-99-111419","article-title":"Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed\/Refractory (r\/r) Multiple Myeloma (MM)","volume":"132","author":"Gregory","year":"2018","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"575609","DOI":"10.3389\/fimmu.2020.575609","article-title":"Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy","volume":"11","author":"Alfarra","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2013","journal-title":"Mol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/01.HS9.0000563116.66927.0a","article-title":"Effects of NKTR-255, a polymer conjugated human IL-15, on efficacy of CD19 CAR T CELL immunotherapy in a preclinical Lymphoma model","volume":"3","author":"Chou","year":"2019","journal-title":"HemaSphere"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2013","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.clml.2017.06.030","article-title":"Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future","volume":"17","author":"Sherbenou","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 axis in multiple myeloma: A dream or a reality?","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: Phase I KEYNOTE -023 study","volume":"186","author":"Mateos","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody\u2013drug conjugate in relapsed or refractory multiple myeloma (BMA117159): A dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/ceo.13995","article-title":"Corneal epithelial toxicity induced by belantamab mafodotin","volume":"49","author":"Ms","year":"2021","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific Antibodies in Multiple Myeloma: Present and Future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2021.39.15_suppl.8008","article-title":"Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) \u00d7 CD3 bispecific antibody, in relapsed\/refractory multiple myeloma (MM)","volume":"39","author":"Berdeja","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-138831","article-title":"Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and\/or Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Garfall","year":"2020","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a Target of Antibody\u2013Drug Conjugates for the Treatment of Multiple Myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia","volume":"18","author":"Polson","year":"2006","journal-title":"Int. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0002-9440(10)63276-2","article-title":"Overexpression of PDZK1 within the 1q12-q22 Amplicon Is Likely To Be Associated with Drug-Resistance Phenotype in Multiple Myeloma","volume":"165","author":"Inoue","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136985","article-title":"Initial Clinical Activity and Safety of BFCR4350A, a FcRH5\/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Nishida, H. (2021). Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. Cancers, 13.","DOI":"10.3390\/cancers13112712"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2019.37.15_suppl.8007","article-title":"Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R\/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study","volume":"37","author":"Topp","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti\u2013B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE\u00ae (bispecific T-cell engager) Molecule, in Relapsed\/Refractory (RR) Multiple Myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.thj.6200115","article-title":"Increased conventional chemotherapy does not improve survival in multiple myeloma: Long-term results of two PETHEMA trials including 914 patients","volume":"2","author":"Miguel","year":"2001","journal-title":"Hematol. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Subklewe","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s11684-019-0714-8","article-title":"Management of cytokine release syndrome related to CAR-T cell therapy","volume":"13","author":"Chen","year":"2019","journal-title":"Front. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2014-11-568923","article-title":"Treatment options for relapsed and refractory multiple myeloma","volume":"125","author":"Nooka","year":"2015","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update","volume":"78","author":"Nijhof","year":"2017","journal-title":"Drugs"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/7\/355\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:38:34Z","timestamp":1760139514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/7\/355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":79,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["curroncol29070355"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29070355","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]}}}